Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  News  >  Companies  >  All News

News : Companies
Latest NewsCompaniesMarketsEconomy & ForexCommoditiesInterest RatesBusiness LeadersFinance ProfessionalsCalendarSectors

Helsinn to co-support a satellite symposium on current and emerging treatments of Acute Myeloid Leukemia (AML) at 24th European Hematology Association (EHA) Congress

share with twitter share with LinkedIn share with facebook
share via e-mail
0
06/12/2019 | 03:31am EDT

Helsinn to co-support a satellite symposium on current and emerging treatments of Acute Myeloid Leukemia (AML) at 24th European Hematology Association (EHA) Congress

  • Symposium will explore the landscape and potential development of treatment options for AML

             

Lugano, Switzerland, June 12, 2019 – Helsinn, a Swiss pharmaceutical group focused on building quality cancer care products, today announces that it will co-support a satellite symposium around current and emerging treatment options for Acute Myeloid Leukemia (AML) at the 24th European Hematology Association (EHA) Congress.

The symposium, titled “Current and Emerging Treatment Options in AML:  Focus on Novel, Targeted Agents”, will be held in Amsterdam, on June 13, 2019, 12.30‐14.00 CEST.

The event targets medical oncologists, haematologists and other healthcare professionals involved in the management of patients with AML. It is designed to provide expert insight into the rapidly evolving treatment landscape for patients and to explore likely developments in treatment over the coming years, and will feature presentations from leaders in the field.

The multi- supported independent symposium is organized by prIME oncology, and the full programme can be found here:

https://www.primebymedscape.org/live-events/heme/targeting-agents-aml-amsterdam-2019/

Silvia Sebastiani, Helsinn Group Head of Medical Affairs, commented: “AML is a rapidly-progressing and often fatal disease for which there are limited treatment options and is one of Helsinn’s core clinical focus areas. We are delighted to be co-supporter of this independent educational symposium, which is designed to provide up-to-the-minute expert insight into the treatment trends and clinical developments in this area.

EHA 2019 will be held from June 13-16, 2019 in Amsterdam. Further details can be found here: https://ehaweb.org/congress/eha24/key-information/

About the Helsinn Group

Helsinn is a privately owned pharmaceutical group with an extensive portfolio of marketed cancer care products and a robust drug development pipeline. Since 1976, Helsinn has been improving the everyday lives of patients, guided by core family values of respect, integrity and quality. The Group works across pharmaceuticals, biotechnology, medical devices and nutritional supplements and has expertise in research, development, manufacture and the commercialization of therapeutic and supportive care products for cancer, pain and inflammation and gastroenterology. In 2016, Helsinn created the Helsinn Investment Fund to support early-stage investment opportunities in areas of unmet patient need. The company is headquartered in Lugano, Switzerland, with operating subsidiaries in Switzerland, Ireland, the U.S., Monaco and China, as well as a product presence in approximately 190 countries globally.

To learn more about Helsinn Group please visit www.helsinn.com

For more information:

Helsinn Group Media Contact

Paola Bonvicini

Group Head of Communication

Lugano, Switzerland

Tel: +41 (0) 91 985 21 21

Info-hhc@helsinn.com

For more information, please visit www.helsinn.com and follow us on TwitterLinkedIn and Vimeo

Primary Logo


© GlobeNewswire 2019
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news "Companies"
07:12pEducational Environmental Forum To Be Held To Address Per- And Polyfluoroalkyl Substances (PFAS)
PR
07:10pSHAREHOLDER ALERT : Robbins Arroyo LLP Is Investigating the Officers and Directors of Sonim Technologies, Inc. (SONM) on Behalf of Shareholders
BU
07:02pRAZOR ENERGY CORP : . Announces Director Resignation
AQ
07:01pUAV Payload and Subsystems Market 2019-2023 - Evolving Opportunities with BAE Systems Plc and Lockheed Martin Corp. | Technavio
BU
06:50pS&P GLOBAL : NVR Set to Join S&P 500; Jefferies Financial Group, II-VI to Join S&P MidCap 400; Callon Petroleum, PriceSmart to Join S&P SmallCap 600
PR
06:47pFORTINET : FortiVet Addresses the Cyber Skills Shortage in Canada
PU
06:47pGOPRO : Employees Swim To Keep Lake Tahoe Blue GoPro Employees Swim To Keep Lake Tahoe Blue
PU
06:42pIMINING BLOCKCHAIN AND CRYPTOCURRENCY : Cancels Financing
PU
06:42pZUORA : When Is A Car Not A Car?
PU
06:39pHIGHLANDS BANKSHARES INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA : Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Highlands Bankshares, Inc. - HLND
BU
Latest news "Companies"